Please provide your email address to receive an email when new articles are posted on . Melanocyte-keratinocyte transplant procedures are rare in the U.S. due to a need for specialized equipment. The ...
AVITA Medical's Spray-On Skin Cells device rapidly processes a patient's own skin to treat large dermatological injuries. The company's sales growth is expected to accelerate in 2024 due to the ...
AVITA Medical: Innovative device to treat skin injuries gaining sales momentum. Recent FDA approvals of full-thickness skin defects and Vitiligo greatly expand addressable market. Expanded sales force ...
Please provide your email address to receive an email when new articles are posted on . Melanocyte keratinocyte transplantation can yield significant repigmentation ranging from 70% to 100%. The ...
VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, ...
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
VALENCIA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted ...
Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results